Regeneron Pharmaceuticals (REGN) is forecasting annual earnings growth of 7.41%, with revenue also projected to rise by 7% ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Regeneron Pharmaceuticals recently saw its Fair Value price target increased from $722.20 to $735.72. This change comes on ...

The FDA has issued another complete response letter (CRL) to Regeneron, rejecting its bid for approval of its prefilled syringe version of high-dose (HD) Eylea—again for unresolved issues at the ...

Regeneron will be responsible for funding preclinical, clinical and commercial development for any ModeX product it chooses to advance from the research pact, with ModeX eligible for milestone ...

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) has entered a license and collaboration deal with OPKO Health’s (Nasdaq: ...

REGN stock is presently trading nearly 38% lower than its 1-year peak, and is also being traded at a P/S multiple that is ...

Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...

Investing.com - Regeneron has posted third-quarter revenue and profit which both topped Wall Street expectations, thanks to ...

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea ...

Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...